Products, Major Customers and Concentrations of Credit Risks

Our primary product groups are infusion therapy, critical care and oncology. The breakdown by market segment for the years ended December 31, 2015, 2014 and 2013 are as follows:



	2015		2014		2013
Infusion therapy	$	244,746	$	216,280	$	221,192
Critical care	54,312		55,074		54,328
Oncology	41,447		36,651		36,857
Other	1,163		1,255		1,339
	$	341,668	$	309,260	$	313,716

We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors, and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. For the years ended December 31, 2015, 2014 and 2013, we had worldwide sales to one manufacturer, Pfizer, of 36%, 36% and 39%, respectively, of consolidated revenue. As of December 31, 2015, and 2014, we had accounts receivable from Pfizer of 40% and 27%, respectively, of consolidated accounts receivable.

Domestic sales accounted for 71%, 69% and 71% of total revenue in 2015, 2014 and 2013, respectively. International sales, which are determined by the destination of the product shipment, accounted for 29%, 31% and 29% of total revenue in 2015, 2014 and 2013, respectively.

The table below presents our gross long-lived assets by country:



	As of December 31,
	2015		2014
Mexico	$	53,462	51,554
Slovakia⁽¹⁾	5,480		16,643
Italy	4,418		4,855
Germany	671		638
Netherlands	49		—
Australia	35		—
Total foreign	$	64,115	$	73,690
United States	158,933		151,024
Worldwide total	$	223,048	$	224,714

____________________________

⁽¹⁾The decrease in Slovakia long-lived assets included an $8.2 million reclass of land and building to assets held for sale, which were subsequently impaired, see Note 6, Impairment of assets held for sale.